Medtronic PLC $MDT Shares Sold by St. James Investment Company LLC

St. James Investment Company LLC lessened its holdings in shares of Medtronic PLC (NYSE:MDT) by 2.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 308,461 shares of the medical technology company’s stock after selling 6,324 shares during the quarter. Medtronic makes up about 4.6% of St. James Investment Company LLC’s portfolio, making the stock its 8th biggest holding. St. James Investment Company LLC’s holdings in Medtronic were worth $29,378,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Delos Wealth Advisors LLC acquired a new stake in Medtronic in the 2nd quarter valued at about $27,000. Corundum Trust Company INC purchased a new stake in shares of Medtronic in the third quarter valued at approximately $27,000. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Medtronic in the third quarter valued at approximately $33,000. Tripletail Wealth Management LLC purchased a new position in Medtronic during the third quarter worth approximately $34,000. Finally, GFG Capital LLC acquired a new position in Medtronic during the second quarter worth $36,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on MDT shares. UBS Group raised their price objective on shares of Medtronic from $95.00 to $102.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 19th. Robert W. Baird set a $103.00 price target on shares of Medtronic in a report on Tuesday, December 16th. Wall Street Zen lowered shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, January 3rd. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research note on Monday, January 5th. Finally, Daiwa Capital Markets upped their price target on Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.28.

Medtronic Stock Down 2.2%

Medtronic stock opened at $96.82 on Tuesday. The company has a market capitalization of $124.12 billion, a PE ratio of 26.10, a price-to-earnings-growth ratio of 2.55 and a beta of 0.71. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The firm has a 50 day moving average price of $99.08 and a 200 day moving average price of $94.99.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.05. The business had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period last year, the firm earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were given a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.9%. Medtronic’s payout ratio is 76.55%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).